Your browser doesn't support javascript.
loading
Center Variation in Intention-to-Treat Survival Among Patients Listed for Liver Transplant.
Kwong, Allison J; Flores, Avegail; Saracino, Giovanna; Boutté, Jodi; McKenna, Greg; Testa, Giuliano; Bahirwani, Ranjeeta; Wall, Anji; Kim, W Ray; Klintmalm, Göran; Trotter, James F; Asrani, Sumeet K.
  • Kwong AJ; Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA.
  • Flores A; Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX.
  • Saracino G; Baylor University Medical Center, Dallas, TX.
  • Boutté J; Baylor University Medical Center, Dallas, TX.
  • McKenna G; Baylor University Medical Center, Dallas, TX.
  • Testa G; Baylor University Medical Center, Dallas, TX.
  • Bahirwani R; Baylor University Medical Center, Dallas, TX.
  • Wall A; Baylor University Medical Center, Dallas, TX.
  • Kim WR; Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA.
  • Klintmalm G; Baylor University Medical Center, Dallas, TX.
  • Trotter JF; Baylor University Medical Center, Dallas, TX.
  • Asrani SK; Baylor University Medical Center, Dallas, TX.
Liver Transpl ; 26(12): 1582-1593, 2020 12.
Article en En | MEDLINE | ID: mdl-32725923
ABSTRACT
In the United States, centers performing liver transplant (LT) are primarily evaluated by patient survival within 1 year after LT, but tight clustering of outcomes allows only a narrow window for evaluation of center variation for quality improvement. Alternate measures more relevant to patients and the transplant community are needed. We examined adults listed for LT in the United States, using data submitted to the Scientific Registry of Transplant Recipients. Intention-to-treat (ITT) survival was defined as survival within 1 year from listing, regardless of transplant. Mixed effects/frailty models were used to assess center variation in ITT survival. Between January 2010 and December 2016, there were 66,428 new listings at 113 centers. Overall, median 1-year ITT survival was 79.8% (interquartile range [IQR], 76.1%-83.4%), whereas 1-year waiting-list (WL) survival was 75.8% (IQR, 71.2%-79.4%), and 1-year post-LT survival was 90.0% (IQR, 87.9%-91.8%). Higher rates of ITT mortality were correlated with increased WL mortality (correlation, r = 0.76), increased post-LT mortality (r = 0.31), lower volume centers (r = -0.34), and lower transplant rate ratio (r = -0.25). Similar patterns were observed in the subgroup of WL candidates listed with Model for End-Stage Liver Disease (MELD) ≥25 median 1-year ITT survival was 65.2% (IQR, 60.2%-72.6%), whereas 1-year post-LT survival was 87.5% (IQR, 84.0%-90.9%), and 1-year WL survival was 36.6% (IQR, 27.9%-47.0%). In mixed effects modeling, the transplant center was an independent predictor of ITT survival even after adjustment for age, sex, MELD, and sociodemographic variables. Center variation for ITT survival was larger compared with post-LT survival. The measurement of ITT outcome offers a complementary method to assess center performance. This is a first step toward understanding differences in program quality beyond patient and graft survival after LT.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Hígado / Enfermedad Hepática en Estado Terminal Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans País como asunto: America do norte Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Hígado / Enfermedad Hepática en Estado Terminal Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans País como asunto: America do norte Idioma: En Año: 2020 Tipo del documento: Article